STAT

Some drugs being tested as Covid-19 treatments could be very cheap to make

Some of the medicines that researchers are studying as potential #coronavirus treatments could be manufactured profitably for as little as $1 to $29 per course of treatment, according to a…
Bottles of Remdesivir in a hospital for Covid-19 patients in Wuhan.

Some existing medicines that may be repurposed to fight Covid-19 could also be manufactured profitably for as little as $1 to $29 per course of treatment, a move that could dramatically widen availability across the globe, according to a new study.

For instance, the researchers calculated that remdesivir, the experimental Gilead Sciences () drug originally tested for Ebola, could be made for just 93 cents for a day’s supply. And a Roche () drug called Esbriet, which is used to treat idiopathic pulmonary fibrosis, could be made for $1.09 for a day’s supply, in the Journal of Virus Eradication.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

Related Books & Audiobooks